Embelin suppresses pancreatic cancer growth by modulating tumor immune microenvironment

Frontiers in Bioscience - Landmark

Volumn 19, Issue 1, 2014, Pages 113-125

  Marsh, Justine L ^a   Jackman, Chris P ^a   Tang, Su Ni ^b   Shankar, Sharmila ^b   Srivastava, Rakesh K ^b  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

Akt; Embelin; Pancreatic cancer; Sonic hedgehog

Indexed keywords

BENZOQUINONE DERIVATIVE; EMBELIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL DIVISION; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; NICK END LABELING; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BENZOQUINONES; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; FLOW CYTOMETRY; HETEROGRAFTS; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84898807499     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4198     Document Type: Article

References (42)

1. Z. Nikolovska-Coleska, L. Xu, Z. Hu, Y. Tomita, P. Li, P. P. Roller, R. Wang, X. Fang, R. Guo, M. Zhang, M. E. Lippman, D. Yang and S. Wang: Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem, 47(10), 2430-40 (2004)
2. M. Xu, J. Cui, H. Fu, P. Proksch, W. Lin and M. Li: Embelin derivatives and their anticancer activity through microtubule disassembly. Planta Med, 71(10), 944-8 (2005)
3. J. Y. Heo, H. J. Kim, S. M. Kim, K. R. Park, S. Y. Park, S. W. Kim, D. Nam, H. J. Jang, S. G. Lee, K. S. Ahn, S. H. Kim, B. S. Shim and S. H. Choi: Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN. Cancer Lett, 308(1), 71-80 (2011)
4. Y. Huang, J. Lu, X. Gao, J. Li, W. Zhao, M. Sun, D. B. Stolz, R. Venkataramanan, L. C. Rohan and S. Li: PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel. Bioconjug Chem, 23(7), 1443-51 (2012)
5. S. W. Kim, S. M. Kim, H. Bae, D. Nam, J. H. Lee, S. G. Lee, B. S. Shim, S. H. Kim, K. S. Ahn, S. H. Choi and G. Sethi: Embelin inhibits growth and induces apoptosis through the suppression of Akt/mTOR/S6K1 signaling cascades. Prostate, 73(3), 296-305 (2013)
6. J. Y. Heo, H. J. Kim, S. M. Kim, K. R. Park, S. Y. Park, S. W. Kim, D. Nam, H. J. Jang, S. G. Lee, K. S. Ahn, S. H. Kim, B. S. Shim, S. H. Choi and K. S. Ahn: Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN. Cancer Lett, 308(1), 71-80 (2011)
7. M. D. Siegelin, T. Gaiser and Y. Siegelin: The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. Neurochem Int, 55(6), 423-30 (2009)
8. A. L. Warshaw and C. Fernandez-del Castillo: Pancreatic carcinoma. N Engl J Med, 326(7), 455-65 (1992)
9. C. J. Magee, P. Ghaneh and J. P. Neoptolemos: Surgical and medical therapy for pancreatic carcinoma. Best Pract Res Clin Gastroenterol, 16(3), 435-55 (2002)
10. D. Li: Molecular epidemiology of pancreatic cancer. Cancer J, 7(4), 259-65 (2001)
11. E. B. Gold and S. B. Goldin: Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am, 7(1), 67-91 (1998)
12. E. M. Jaffee, R. H. Hruban, M. Canto and S. E. Kern: Focus on pancreas cancer. Cancer Cell, 2(1), 25-8 (2002)
13. Z. Wang, Y. Li, A. Ahmad, S. Banerjee, A. S. Azmi, D. Kong and F. H. Sarkar: Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol, 8(1), 27-33 (2011)
14. J. Li, M. G. Wientjes and J. L. Au: Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J, 12(2), 223-32 (2010)
15. A. Arlt, S. S. Muerkoster and H. Schafer: Targeting apoptosis pathways in pancreatic cancer. Cancer Lett (2010)
16. A. L. Kennedy, P. D. Adams and J. P. Morton: Ras, PI3K/Akt and senescence: Paradoxes provide clues for pancreatic cancer therapy. Small GTPases, 2(5), 264-267 (2011)
17. R. Hill, J. H. Calvopina, C. Kim, Y. Wang, D. W. Dawson, T. R. Donahue, S. Dry and H. Wu: PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res, 70(18), 7114-24 (2010)
18. S. Shankar, D. Nall, S. N. Tang, D. Meeker, J. Passarini, J. Sharma and R. K. Srivastava: Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One, 6(1), e16530 (2011)
19. R. Rohatgi and M. P. Scott: Patching the gaps in Hedgehog signalling. Nat Cell Biol, 9(9), 1005-9 (2007)
20. K. W. Kinzler, J. M. Ruppert, S. H. Bigner and B. Vogelstein: The GLI gene is a member of the Kruppel family of zinc finger proteins. Nature, 332(6162), 371-4 (1988)
21. S. Shankar, Q. Chen and R. K. Srivastava: Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. J Mol Signal, 3, 7 (2008)
22. S. Shankar, S. Ganapathy, S. R. Hingorani and R. K. Srivastava: EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci, 13, 440-52 (2008)
23. G. Basanez, L. Soane and J. M. Hardwick: A new view of the lethal apoptotic pore. PLoS Biol, 10(9), e1001399 (2012)
24. M. H. Harris and C. B. Thompson: The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ, 7(12), 1182-91 (2000)
25. M. G. Vander Heiden and C. B. Thompson: Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol, 1(8), E209-16 (1999)
26. H. Harada and S. Grant: Apoptosis regulators. Rev Clin Exp Hematol, 7(2), 117-38 (2003)
27. J. Folkman: Angiogenesis and proteins of the hemostatic system. J Thromb Haemost, 1(8), 1681-2 (2003)
28. R. Hill, Y. Li, L. M. Tran, S. Dry, J. H. Calvopina, A. Garcia, C. Kim, Y. Wang, T. R. Donahue, H. R. Herschman and H. Wu: Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther, 11(10), 2127-37 (2012)
29. C. Palena, D. H. Hamilton and R. I. Fernando: Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol, 8(6), 713-22 (2012)
30. R. I. Fernando, M. D. Castillo, M. Litzinger, D. H. Hamilton and C. Palena: IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res, 71(15), 5296-306 (2011)
31. P. S. Steeg: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med, 12(8), 895-904 (2006)
32. S. Kraljevic Pavelic, M. Sedic, H. Bosnjak, S. Spaventi and K. Pavelic: Metastasis: new perspectives on an old problem. Mol Cancer, 10, 22 (2011)
33. B. N. Singh, J. Fu, R. K. Srivastava and S. Shankar: Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One, 6(11), e27306 (2011)
34. D. A. Altomare, S. Tanno, A. De Rienzo, A. J. Klein-Szanto, S. Tanno, K. L. Skele, J. P. Hoffman and J. R. Testa: Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem, 88(1), 470-6 (2003)
35. A. Maitra and R. H. Hruban: A new mouse model of pancreatic cancer: PTEN gets its Akt together. Cancer Cell, 8(3), 171-2 (2005)
36. S. P. Thayer, M. P. di Magliano, P. W. Heiser, C. M. Nielsen, D. J. Roberts, G. Y. Lauwers, Y. P. Qi, S. Gysin, C. Fernandez-del Castillo, V. Yajnik, B. Antoniu, M. McMahon, A. L. Warshaw and M. Hebrok: Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature, 425(6960), 851-6 (2003)
37. S. H. Li, J. Fu, D. N. Watkins, R. K. Srivastava and S. Shankar: Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway. Mol Cell Biochem, 373(1-2), 217-27 (2013)
38. M. Rodova, J. Fu, D. N. Watkins, R. K. Srivastava and S. Shankar: Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal. PLoS One, 7(9), e46083 (2012)
39. S. N. Tang, C. Singh, D. Nall, D. Meeker, S. Shankar and R. K. Srivastava: The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal, 5, 14 (2010)
40. K. Hao, X. D. Tian, C. F. Qin, X. H. Xie and Y. M. Yang: Hedgehog signaling pathway regulates human pancreatic cancer cell proliferation and metastasis. Oncol Rep, 29(3), 1124-32 (2013)
41. R. K. Srivastava, S. N. Tang, W. Zhu, D. Meeker and S. Shankar: Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells. Front Biosci (Elite Ed), 3, 515-28 (2011)
42. S. N. Tang, J. Fu, D. Nall, M. Rodova, S. Shankar and R. K. Srivastava: Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer, 131(1), 30-40 (2012)